The effect and safety of dulaglutide for hyperglycemia associated with R-CHOP thepapy

JRCT ID: jRCT1031200022

Registered date:27/04/2020

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Malignant lymphoma
• Date of first enrollment: 27/04/2020
• Target sample size: 10
• Study type: Interventional
• Intervention(s): Administer duraglutide once a week

Outcome(s)

• Primary Outcome: HbA1C rate of change before treatment and 1.2.3.4.5.6 months after the start of dulaglutide

Secondary Outcome

(1) The incidence of hypoglycemia
(2) Insulin consumption per body weight
(3) Decrease in fasting blood glucose before treatment
(4) Glycoalbumin change before treatment and 1.2.3.4.5.6 months after duraglutide

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

(1) Patients recieved R-CHOP therapy for malignant lymphoma
(2) ECOG performance status score 0-2
(3) Patients dignosed with Type2 diabetes, or Patients who have been found twice by repeated tests of either fasting blood glucose of 126 mg / dl or more and blood glucose of 200 mg / dl or more during first chemotherapy
(4) Patients who are not allergic to dulaglutide
(5) Patients who have never used duraglutide before
(6) Patients with written consent

Exclude criteria

(1) Patients with a history of hyperglycemic coma and diabetic ketoacidosis
(2) Patients with type 1 diabetes
(3) Patients judged by the researcher to be inappropriate as subjects

Related Information

• Primary Sponsor: Suyama Takuya